349 related articles for article (PubMed ID: 32879051)
1. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
2. Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development.
Gui X; Deng M; Song H; Chen Y; Xie J; Li Z; He L; Huang F; Xu Y; Anami Y; Yu H; Yu C; Li L; Yuan Z; Xu X; Wang Q; Chai Y; Huang T; Shi Y; Tsuchikama K; Liao XC; Xia N; Gao GF; Zhang N; Zhang CC; An Z
Cancer Immunol Res; 2019 Aug; 7(8):1244-1257. PubMed ID: 31213474
[TBL] [Abstract][Full Text] [Related]
3. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
4. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation.
Churchill HRO; Fuda FS; Xu J; Deng M; Zhang CC; An Z; Zhang N; Chen P; Bergstrom C; Kansagra A; Collins R; John S; Koduru P; Chen W
Cytometry B Clin Cytom; 2021 Jul; 100(4):476-487. PubMed ID: 32918786
[TBL] [Abstract][Full Text] [Related]
6. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
7. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
[TBL] [Abstract][Full Text] [Related]
8. De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy.
Feng H; Liu Y; Zhang M; Liu R; Wang J; Wang W; He P; Zhang P; Niu F
Biochem Biophys Res Commun; 2022 Nov; 629():152-158. PubMed ID: 36122452
[TBL] [Abstract][Full Text] [Related]
9. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.
John S; Chen H; Deng M; Gui X; Wu G; Chen W; Li Z; Zhang N; An Z; Zhang CC
Mol Ther; 2018 Oct; 26(10):2487-2495. PubMed ID: 30131301
[TBL] [Abstract][Full Text] [Related]
10. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
11. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
12. CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation.
Abadir E; Gasiorowski RE; Lai K; Kupresanin F; Romano A; Silveira PA; Lo TH; Fromm PD; Kennerson ML; Iland HJ; Ho PJ; Hogarth PM; Bradstock K; Hart DNJ; Clark GJ
Mol Oncol; 2019 Oct; 13(10):2107-2120. PubMed ID: 31338922
[TBL] [Abstract][Full Text] [Related]
13. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
[TBL] [Abstract][Full Text] [Related]
14. Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy.
Dai Z; Zhang XN; Cheng Q; Fei F; Hou T; Li J; Abdolvahabi A; Watanabe J; Pei H; Smbatyan G; Xie J; Lenz HJ; Louie SG; Zhang Y
J Control Release; 2021 Aug; 336():433-442. PubMed ID: 34197861
[TBL] [Abstract][Full Text] [Related]
15. ImmunoPET, [
Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK
Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348
[TBL] [Abstract][Full Text] [Related]
16. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
Deng M; Gui X; Kim J; Xie L; Chen W; Li Z; He L; Chen Y; Chen H; Luo W; Lu Z; Xie J; Churchill H; Xu Y; Zhou Z; Wu G; Yu C; John S; Hirayasu K; Nguyen N; Liu X; Huang F; Li L; Deng H; Tang H; Sadek AH; Zhang L; Huang T; Zou Y; Chen B; Zhu H; Arase H; Xia N; Jiang Y; Collins R; You MJ; Homsi J; Unni N; Lewis C; Chen GQ; Fu YX; Liao XC; An Z; Zheng J; Zhang N; Zhang CC
Nature; 2018 Oct; 562(7728):605-609. PubMed ID: 30333625
[TBL] [Abstract][Full Text] [Related]
17. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
Cianfriglia M
Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
[TBL] [Abstract][Full Text] [Related]
18. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.
Nielsen CF; van Putten SM; Lund IK; Melander MC; Nørregaard KS; Jürgensen HJ; Reckzeh K; Christensen KR; Ingvarsen SZ; Gårdsvoll H; Jensen KE; Hamerlik P; Engelholm LH; Behrendt N
Oncotarget; 2017 Jul; 8(27):44605-44624. PubMed ID: 28574834
[TBL] [Abstract][Full Text] [Related]
19. Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML.
Morse JW; Gui X; Deng M; Huang R; Ye X; Zhao P; Fan X; Xiong W; Zhang C; Zhang N; An Z
Antib Ther; 2024 Jan; 7(1):13-27. PubMed ID: 38235377
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
